Joseph Klein III sold $960k of IONS
director at IONIS PHARMACEUTICALS INC. 12,000 shares at an average of $80.00, traded Nov 25, 2025, filed Nov 28, 2025.
Score components
- +15RoleDirector
- +24Trade size$960k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.4%, 3m -1.9%, 6m -7.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000874015-25-000286, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 25, 2025 | MOption exercise Common Stockindirect: by Trust10b5-1 | +4,000 | $0.00 | $0 | 4,000 | Nov 28, 2025 |
| Nov 25, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -4,000 | $80.00 | $320k | 0 | Nov 28, 2025 |
| Nov 25, 2025 | MOption exercise Common Stockindirect: by Trust10b5-1 | +4,000 | $0.00 | $0 | 4,000 | Nov 28, 2025 |
| Nov 25, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -4,000 | $80.00 | $320k | 0 | Nov 28, 2025 |
| Nov 25, 2025 | MOption exercise Common Stockindirect: by Trust10b5-1 | +4,000 | $0.00 | $0 | 4,000 | Nov 28, 2025 |
| Nov 25, 2025 | SOpen-market sale Common Stockindirect: by Trust10b5-1 | -4,000 | $80.00 | $320k | 0 | Nov 28, 2025 |
| Nov 25, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Trust10b5-1 | -4,000 | $0.00 | $0 | 8,000 | Nov 28, 2025 |
| Nov 25, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Trust10b5-1 | -4,000 | $0.00 | $0 | 4,000 | Nov 28, 2025 |
| Nov 25, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivativeindirect: by Trust10b5-1 | -4,000 | $0.00 | $0 | 0 | Nov 28, 2025 |
Related signals
Other insiders at IONIS PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | IONIS PHARMACEUTICALS INC | Joseph Baroldi EVP, Chief Business Officer | $452k 5,635 shares | -55% | |
| 30Weak | IONIS PHARMACEUTICALS INC | Eugene Schneider EVP, Chf Clinical Develop Ofcr | $2.1M 26,000 shares | -25% | |
| 23Weak | IONIS PHARMACEUTICALS INC | Patrick R. O'Neil EVP CLO & General Counsel | $246k 3,069 shares | -5% | |
| 43Moderate | IONIS PHARMACEUTICALS INC | Eric Swayze EVP Research | $839k 10,602 shares | -33% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Brett P Monia Chief Executive Officer | $6.8M 85,637 shares | -33% | |
| 14Weak | IONIS PHARMACEUTICALS INC | Spencer R Berthelsen director | $588k 8,000 shares | -5% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Holly B. Kordasiewicz EVP, Chief Development Officer | $4.5M 60,846 shares | -73% | |
| 7Weak | IONIS PHARMACEUTICALS INC | Spencer R Berthelsen director | $605k 8,000 shares | -5% | |
| 20Weak | IONIS PHARMACEUTICALS INC | Brett P Monia Chief Executive Officer | $356k 4,536 shares | -2% | |
| 40Moderate | IONIS PHARMACEUTICALS INC | Joseph Loscalzo director | $5.8M 77,289 shares | -68% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.